Literature DB >> 32391930

A one-pot radiosynthesis of [18 F]PARPi.

Thomas C Wilson1, Nagavarakishore Pillarsetty1,2, Thomas Reiner1,2,3.   

Abstract

In this paper, we disclose a new strategy for the radiosynthesis of [18 F]PARPi from the corresponding, boc-protected, nitro-precursor. Using a two-step procedure, [18 F]PARPi could be isolated in radiochemical yields up to 9.6%. The reaction proceeds via an efficient one-pot, two-step process, allowing for simplification over previous methods that require complex multi-step, multi-pot strategies to be implemented.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Olaparib; PARP inhibitor; PET chemistry; [18F]PARPi; fluorine-18; radiochemistry

Year:  2020        PMID： 32391930      PMCID： PMC7551923          DOI： 10.1002/jlcr.3847

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN： 0362-4803            Impact factor:   1.921


  34 in total

Review 1.  PARP inhibition: PARP1 and beyond.

Authors:  Michèle Rouleau; Anand Patel; Michael J Hendzel; Scott H Kaufmann; Guy G Poirier
Journal:  Nat Rev Cancer       Date:  2010-03-04       Impact factor: 60.716

2.  PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.

Authors:  Stephen A Jannetti; Giuseppe Carlucci; Brandon Carney; Susanne Kossatz; Larissa Shenker; Lukas M Carter; Beatriz Salinas; Christian Brand; Ahmad Sadique; Patrick L Donabedian; Kristen M Cunanan; Mithat Gönen; Vladimir Ponomarev; Brian M Zeglis; Mark M Souweidane; Jason S Lewis; Wolfgang A Weber; John L Humm; Thomas Reiner
Journal:  J Nucl Med       Date:  2018-03-23       Impact factor: 10.057

3.  Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.

Authors:  Giuseppe Carlucci; Brandon Carney; Christian Brand; Susanne Kossatz; Christopher P Irwin; Sean D Carlin; Edmund J Keliher; Wolfgang Weber; Thomas Reiner
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

4.  Derisking the Cu-Mediated 18F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands.

Authors:  Nicholas J Taylor; Enrico Emer; Sean Preshlock; Michael Schedler; Matthew Tredwell; Stefan Verhoog; Joel Mercier; Christophe Genicot; Véronique Gouverneur
Journal:  J Am Chem Soc       Date:  2017-06-12       Impact factor: 15.419

5.  Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer.

Authors:  Heiko Schöder; Paula Demétrio De Souza França; Reiko Nakajima; Eva Burnazi; Sheryl Roberts; Christian Brand; Milan Grkovski; Audrey Mauguen; Mark P Dunphy; Ronald A Ghossein; Serge K Lyashchenko; Jason S Lewis; Joseph A O'Donoghue; Ian Ganly; Snehal G Patel; Nancy Y Lee; Thomas Reiner
Journal:  Clin Cancer Res       Date:  2020-04-03       Impact factor: 12.531

6.  Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.

Authors:  Brandon Carney; Giuseppe Carlucci; Beatriz Salinas; Valentina Di Gialleonardo; Susanne Kossatz; Axel Vansteene; Valerie A Longo; Alexander Bolaender; Gabriela Chiosis; Kayvan R Keshari; Wolfgang A Weber; Thomas Reiner
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

7.  Manual and automated Cu-mediated radiosynthesis of the PARP inhibitor [18F]olaparib.

Authors:  Florian Guibbal; Patrick G Isenegger; Thomas C Wilson; Anna Pacelli; Damien Mahaut; Jeroen B I Sap; Nicholas J Taylor; Stefan Verhoog; Sean Preshlock; Rebekka Hueting; Bart Cornelissen; Véronique Gouverneur
Journal:  Nat Protoc       Date:  2020-02-28       Impact factor: 13.491

Review 8.  Reverse the Resistance to PARP Inhibitors.

Authors:  Yevgeniy Kim; Aleksei Kim; Ainur Sharip; Aigul Sharip; Juhong Jiang; Qing Yang; Yingqiu Xie
Journal:  Int J Biol Sci       Date:  2017-02-17       Impact factor: 6.580

Review 9.  PARP inhibitors in the management of breast cancer: current data and future prospects.

Authors:  Luca Livraghi; Judy E Garber
Journal:  BMC Med       Date:  2015-08-13       Impact factor: 8.775

10.  PET Imaging of PARP Expression Using 18F-Olaparib.

Authors:  Thomas C Wilson; Mary-Ann Xavier; James Knight; Stefan Verhoog; Julia Baguña Torres; Michael Mosley; Samantha L Hopkins; Sheena Wallington; Phillip D Allen; Veerle Kersemans; Rebekka Hueting; Sean Smart; Véronique Gouverneur; Bart Cornelissen
Journal:  J Nucl Med       Date:  2018-11-02       Impact factor: 10.057
View more
  3 in total

1.  Two experts and a newbie: [18F]PARPi vs [18F]FTT vs [18F]FPyPARP-a comparison of PARP imaging agents.

Authors:  Sophie Stotz; Johannes Kinzler; Anne T Nies; Matthias Schwab; Andreas Maurer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-09-06       Impact factor: 9.236

Review 2.  DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.

Authors:  Nghia T Nguyen; Anna Pacelli; Michael Nader; Susanne Kossatz
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

3.  Fully Automated, High-Dose Radiosynthesis of [18F]PARPi.

Authors:  Anna Pacelli; Fadi Zarrad; Wolfgang P Fendler; Ken Herrmann; Michael Nader
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.